Rapid and objective CT scan prognostic scoring identifies metastatic patients with long-term clinical benefit on anti-PD-1/-L1 therapy
- 1 September 2016
- journal article
- Published by Elsevier in European Journal of Cancer
- Vol. 65, 33-42
Abstract
No abstract availableKeywords
Funding Information
- Philanthropia Foundation
This publication has 27 references indexed in Scilit:
- Trial watchOncoImmunology, 2012
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in CancerNew England Journal of Medicine, 2012
- Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion SequencingNew England Journal of Medicine, 2012
- Sarcopenia as a Prognostic Factor among Patients with Stage III MelanomaAnnals of Surgical Oncology, 2011
- Improved Endpoints for Cancer Immunotherapy TrialsJNCI: Journal of the National Cancer Institute, 2010
- Improved Survival with Ipilimumab in Patients with Metastatic MelanomaNew England Journal of Medicine, 2010
- Association of Skeletal Muscle Wasting With Treatment With Sorafenib in Patients With Advanced Renal Cell Carcinoma: Results From a Placebo-Controlled StudyJournal of Clinical Oncology, 2010
- Final Version of 2009 AJCC Melanoma Staging and ClassificationJournal of Clinical Oncology, 2009
- Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response CriteriaClinical Cancer Research, 2009
- Clinical outcome and prognostic factors for patients treated within the context of a phase I study: the Royal Marsden Hospital experienceBritish Journal of Cancer, 2008